{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:54:41Z","timestamp":1793386481688,"version":"4.5.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T00:00:00Z","timestamp":1596412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T00:00:00Z","timestamp":1596412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Objective<\/jats:title>\n<jats:p>The use of intrapleural tissue plasminogen activator (tPA) and dornase alfa (DNase) is common in the management of pleural space infection. We review our experience with the efficacy and safety of this therapy. We performed a single center, retrospective study of consecutive patients with complicated parapneumonic effusion or empyema who received tPA\/DNase therapy. Treatment success was defined as radiographic and clinical improvement in pleural space infection that precluded the need for surgical intervention, and the absence of mortality related to pleural infection.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Fifty-six patients received concurrent once daily tPA\/DNase therapy (median 3\u00a0days) from July 2014 to July 2019. Fifty-two patients (92.9%) had treatment success. Median duration of chest tube therapy was 10\u00a0days and length of stay was 15\u00a0days. Significant pleural bleeding requiring transfusion therapy occurred in five patients (8.9%). Of these, three patients (5.4%) required operative intervention. Concurrent once daily administration of tPA\/DNase in patients with pleural infection yielded comparable rates of treatment success as compared to twice daily concurrent or sequential administration. However, adverse events highlight potential safety concerns with using once daily concurrent administration of tPA\/DNAse.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13104-020-05210-2","type":"journal-article","created":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T12:06:34Z","timestamp":1596456394000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Clinical efficacy and bleeding outcomes of tissue plasminogen activator and dornase alfa in pleural space infection with once daily concurrent administration: a retrospective cohort study"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1601-6854","authenticated-orcid":false,"given":"Chuan","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Cervellione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Thurm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,3]]},"reference":[{"key":"5210_CR1","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.thorsurg.2012.04.007","volume":"22","author":"MD Taylor","year":"2012","unstructured":"Taylor MD, Kozower BD. Surgical spectrum in the management of empyemas. Thorac Surg Clin. 2012;22:431\u201340.","journal-title":"Thorac Surg Clin"},{"key":"5210_CR2","doi-asserted-by":"publisher","first-page":"e129","DOI":"10.1016\/j.jtcvs.2017.01.030","volume":"153","author":"KR Shen","year":"2017","unstructured":"Shen KR, Bribriesco A, Crabtree T, et al. The American Association for Thoracic Surgery Consensus guidelines for the management of empyema. J Thorac Cardiovasc Surg. 2017;153:e129\u201346.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"5210_CR3","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1055\/s-0033-1334486","volume":"39","author":"T Tucker","year":"2013","unstructured":"Tucker T, Idell S. Plasminogen-plasmin system in the pathogenesis and treatment of lung and pleural injury. Semin Thromb Hemost. 2013;39:373\u201381.","journal-title":"Semin Thromb Hemost"},{"key":"5210_CR4","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1012740","volume":"365","author":"NM Rahman","year":"2011","unstructured":"Rahman NM, Maskell NA, West A, et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N Engl J Med. 2011;365:518\u201326.","journal-title":"N Engl J Med"},{"issue":"9","key":"5210_CR5","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1513\/AnnalsATS.201407-329OC","volume":"11","author":"F Piccolo","year":"2014","unstructured":"Piccolo F, Pitman N, Bhatnagar R, et al. Intrapleural tissue plasminogen activator and deoxyribonuclease for pleural infection: an effective and safe alternative to surgery. Ann Am Thorac Soc. 2014;11(9):1419\u201325.","journal-title":"Ann Am Thorac Soc"},{"key":"5210_CR6","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1097\/MCP.0000000000000164","volume":"21","author":"JM Porcel","year":"2015","unstructured":"Porcel JM. Distinguishing complicated from uncomplicated parapneumonic effusion. Curr Opin Pulm Med. 2015;21:346\u201351.","journal-title":"Curr Opin Pulm Med"},{"key":"5210_CR7","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C, The Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicine products in non-surgical patients. J Thromb Haemost. 2005;3:692\u20134.","journal-title":"J Thromb Haemost"},{"issue":"6","key":"5210_CR8","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/j.athoracsur.2018.02.027","volume":"105","author":"TR Semenkovich","year":"2018","unstructured":"Semenkovich TR, Olsen MA, Puri V, Meyers BF, Kozower BD. Current statement of empyema management. Ann Thorac Surg. 2018;105(6):1589\u201396.","journal-title":"Ann Thorac Surg"},{"key":"5210_CR9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1159\/000443334","volume":"91","author":"HJ Mehta","year":"2016","unstructured":"Mehta HJ, Biswas A, Penley AM, Cope K, Barnes M, Jantz MA. Management of intrapleural sepsis with once daily use of tissue plasminogen activator and deoxyribonuclease. Respiration. 2016;91:101\u20136.","journal-title":"Respiration"},{"key":"5210_CR10","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s00408-015-9807-6","volume":"193","author":"C Aleman","year":"2015","unstructured":"Aleman C, Porcel JM, Alegre J, et al. Intrapleural fibrinolysis with urokinase versus alteplase in complicated parapneumonic PLeural Effusions and Empyema: a prospective randomized study. Lung. 2015;193:993\u20131000.","journal-title":"Lung"},{"key":"5210_CR11","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1097\/01.TA.0000141879.67441.52","volume":"57","author":"DA Skeete","year":"2004","unstructured":"Skeete DA, Rutherford EJ, Schlidt SA, Abrams JE, Parker LA, Rich PB. Intrapleural tissue plasminogen activator for complicated pleural Effusions. J Trauma. 2004;57:1178\u201383.","journal-title":"J Trauma"},{"key":"5210_CR12","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.rmed.2012.02.005","volume":"106","author":"G Thommi","year":"2012","unstructured":"Thommi G, Shehan JC, Robison KL, Christensen M, Backemeyer LA, McLeay MT. A double blind randomized crossover trial comparing rate of decortication and efficacy of intrapleural instillation of alteplase vs placebo in patients with empyemas and complicated parapneumonic effusions. Respir Med. 2012;106:716\u201323.","journal-title":"Respir Med"},{"issue":"9","key":"5210_CR13","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1513\/AnnalsATS.201602-127OC","volume":"13","author":"A Majid","year":"2016","unstructured":"Majid A, Kheir F, Folch A, et al. Concurrent intrapleural instillation of tissue plasminogen activator and DNase for pleural infection. A single center experience. Ann ATS. 2016;13(9):1512\u20138.","journal-title":"Ann ATS"},{"issue":"6","key":"5210_CR14","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1513\/AnnalsATS.201609-673OC","volume":"14","author":"N Popowicz","year":"2017","unstructured":"Popowicz N, Bintcliffe O, De Fonseka D, et al. Dose de-escalation of intrapleural tissue plasminogen activator therapy for pleural infection: the ADAPT project. Ann Am Thorac Soc. 2017;14(6):929\u201336.","journal-title":"Ann Am Thorac Soc"},{"issue":"2","key":"5210_CR15","first-page":"e2214","volume":"19","author":"A Innabi","year":"2018","unstructured":"Innabi A, Surana A, Alzghoul B, Meena N. Rethinking the doses of tissue plasminogen activator and deoxyribonuclease administered concurrently for intrapleural therapy for complicated pleural effusion and empyema. Cureus. 2018;19(2):e2214.","journal-title":"Cureus"},{"key":"5210_CR16","doi-asserted-by":"crossref","unstructured":"McClune JR, Wilshire CL, Gorden JA, et al. Safety and efficacy of intrapleural tissue plasminogen activator and DNase during extended use in complicated pleural space infections. Can Respir J. 2016, Article ID 9796768, 6 pages.","DOI":"10.1155\/2016\/9796768"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-020-05210-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13104-020-05210-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-020-05210-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T00:02:52Z","timestamp":1627948972000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-020-05210-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,3]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5210"],"URL":"https:\/\/doi.org\/10.1186\/s13104-020-05210-2","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,3]]},"assertion":[{"value":"15 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Jamaica Hospital Medical Center Institutional Review Board (IRB# 1527223). Our medical center is located within the United States of America.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors report no financial disclosures or ethical conflicts of interest regarding this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"368"}}